Get notified of page updates
Sign Up for FORCE Newsletters
The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
I am here to learn about:

Genetics and Colorectal Cancer

LGBTQIA+ and Cancer

Genetic Testing

Lynch Syndrome

Women with Mutations

Men with Mutations

Genetics and Ovarian Cancer

Family History and Outreach

Genetics and Breast Cancer

Genetics and Pancreatic Cancer

I've Tested Positive, Now What?

Information for Healthcare Professionals

Biomarker Testing

Managing Menopause

Genetics and Prostate Cancer

Genetics and Endometrial Cancer

Information for Researchers

Enroll in Research > Research Search & Enroll Tool > A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes
A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes

Clinicaltrials.gov identifier:
NCT04171700


Study Contact Information:

Principal Investigator:

Kim Reiss-Binder, MD

University of Pennsylvania

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes (LODESTAR)

About the Study

The LODESTAR study is evaluating the response of the rucaparib in people with advanced (including breast, ovarian, pancreatic, and other cancers) who have an inherited mutation or an acquired mutation in any of the following genes: , , , , , , , FANCA, , RAD51 or RAD51B.  NOTE: This study is no longer enrolling people.   

 

 

This Study is Open To:

 NOTE: This study is no longer enrolling people.

This Study is Not Open To:

 NOTE: This study is no longer enrolling people.